FCM

DRUG2 trials

Sponsors

Ludwig-Maximilians - University of Munich, AMAG Pharmaceuticals, Inc.

Conditions

Iron Deficiency AnemiaLymphoma, FollicularLymphoma, Intermediate-GradeLymphoma, Low-Grade

Phase 3

FCM Versus R-FCM Followed by R-Maintenance or Observation Only

Ludwig-Maximilians - University of MunichLymphoma, Follicular, Lymphoma, Intermediate-Grade, Lymphoma, Low-Grade

Start: 1998-11-30End: 2021-06-30Updated: 2021-05-07

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

CompletedNCT02694978

AMAG Pharmaceuticals, Inc.Iron Deficiency Anemia

Start: 2016-02-29End: 2017-07-17Updated: 2023-07-25

Related Papers

S1268 Effects of Ferric Carboxymaltose vs Ferumoxytol on Hypophosphatemia in Patients With Iron-Deficiency Anemia Due to Gastrointestinal Disorders

The American Journal of Gastroenterology2020-10-01

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

Blood2019-11-131 citations

Randomized trial of intravenous iron-induced hypophosphatemia

JCI Insight2018-12-05188 citations

P608 IV iron treatment of iron deficiency anaemia with ferumoxytol in patients with inflammatory bowel disease unable to take oral iron: A randomised controlled trial vs. ferric carboxymaltose

Journal of Crohn s and Colitis2018-01-162 citations

Randomized, Double-Blind Trial of Ferumoxytol Compared to Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia: Safety and Efficacy

Blood2017-12-07